The USE of tadalafil to treat lower urinary tract symptoms and erectile dysfunction in MEN with benign prostatic hyperplasia: a systematic review
Abstract
Aim of the study \nSeveral clinical trials have extensively investigated the efficacy and safety of chronic treatment with PDE5- Inhibitors (PDE5-I), alone or in combination with alpha blockers, in ameliorating LUTS in men with or without erectile dysfunction (ED). In particular, tadalafil represents one of the most extensively investigated. The aim of present study is to perform a systematic review of the current literature concerning the use of tadalafil for the treatment of LUTS and ED in men with BPH. \n \nMaterials and methods \nAn wide Medline search was performed including the combination of following words: “LUTS”, “BPH”, “PDE5-Is”, “ED”, “tadalafil”. No temporary limits were adopted. IIEF-5 (International Index of Erectile Function), IPSS (International Prostate Symptom Score) and Maximum urinary flow rate (Qmax) were the validated efficacy outcomes. We also evaluated the most common adverse events (AEs) reported for tadalafil in selected studies. \n \nResults \nOut of 96 retrieved articles, 87 were excluded for missing or incomplete data (baseline data, standard deviation), deficiency in methodology (several biases not included), assessment of clinical outcomes without validated instruments. Data from 9 RCTs were included in the present review, for a total of 1936 treated patients with tadalafil daily administration for a mean duration of 12 weeks. Seven RCTs reported the efficacy of daily administration of tadalafil 5mg in relieving LUTS in terms of significant…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,936 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.